As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit ...
Novo Nordisk's Q4 results hinge on Ozempic and Wegovy sales as demand growth slows amid guidance cuts due to intense rivalry and compounded drug headwinds.
With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...
Everyday Health on MSN
Zepbound vs. Wegovy: Which obesity treatment might be right for you?
Wegovy and Zepbound are two FDA-approved weight loss drugs. Learn how they compare in benefits, side effects, and more to ...
The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.
By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" ...
The FDA said it wants suicide warnings to be taken off some popular weight-loss medications following a comprehensive safety ...
The source of this renewed optimism lies in concrete figures related to the U.S. launch of the oral Wegovy variant in January 2026. Market observers believe the daily pill could be a decisive factor ...
Investor's Business Daily on MSN
Novo's Wegovy pill is following in Zepbound's footsteps — and it's only been one week
Novo Nordisk's oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday as Novo ...
By Mariam Sunny Jan 13 (Reuters) - The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential ...
Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its ...
Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results